These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Is it possible to reduce the number of patients studied in drug tests before the drug tested is authorized for marketing?]. Flamant R; Spriet A; Caulin C; Doyon F; Cazor JL; Jaillon P Therapie; 1993; 48(4):329-31. PubMed ID: 8128418 [No Abstract] [Full Text] [Related]
24. Quality control and quality assurance in HIV prevention research: model from a multisite HIV prevention trial. NIMH Multisite HIV Prevention Trial. AIDS; 1997 Dec; 11 Suppl 2():S49-53. PubMed ID: 9475711 [No Abstract] [Full Text] [Related]
26. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. El-Maraghi RH; Eisenhauer EA J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606 [TBL] [Abstract][Full Text] [Related]
27. Biotech's next big blowup? Stires D Fortune; 2002 Mar; 145(6):154. PubMed ID: 11913033 [No Abstract] [Full Text] [Related]
28. Assessing the quality of randomized controlled trials: quality of design is not the only relevant variable. Berk PD; Sacks HS Hepatology; 1999 Nov; 30(5):1332-4. PubMed ID: 10534359 [No Abstract] [Full Text] [Related]
29. FDA perspective on specifications for biotechnology products--from IND to PLA. Murano G Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677 [TBL] [Abstract][Full Text] [Related]
30. [Sweden can contribute to safer drug assessment]. Strandberg K Lakartidningen; 2006 Jun 8-13; 103(23):1853-5. PubMed ID: 16838598 [No Abstract] [Full Text] [Related]
31. Can "phase IV" trials work for you? Borfitz D Med Econ; 2003 Jun; 80(11):58, 64, 67. PubMed ID: 12828120 [No Abstract] [Full Text] [Related]
32. Cutting the cost of drug development? Rawlins MD Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531 [No Abstract] [Full Text] [Related]
33. Methodological quality and reporting of ethical requirements in phase III cancer trials. Tuech JJ; Pessaux P; Moutel G; Thoma V; Schraub S; Herve C J Med Ethics; 2005 May; 31(5):251-5. PubMed ID: 15863678 [TBL] [Abstract][Full Text] [Related]
34. Fables or foibles: inherent problems with RCTs. Rosner A J Manipulative Physiol Ther; 2003 Sep; 26(7):460-7. PubMed ID: 12975633 [No Abstract] [Full Text] [Related]
35. A 25-year review of sequential methodology in clinical studies. Todd S Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691 [TBL] [Abstract][Full Text] [Related]
36. [Without education no development. Extensive program of courses assure the quality]. Einarsson M; Lemne C; Melander H; Rane A Lakartidningen; 1997 Aug; 94(34):2835-7. PubMed ID: 9303994 [No Abstract] [Full Text] [Related]
37. Early stopping for benefit in National Cancer Institute-sponsored randomized Phase III trials: the system is working. Sargent D J Clin Oncol; 2009 Apr; 27(10):1543-4. PubMed ID: 19237627 [No Abstract] [Full Text] [Related]